Investigation and Comparison of Diagnosis and Treatment Guidelines for Community Acquired Pneumonia in terms of Pharmaceutical Care Requirements

Creative Commons License

Bahap M., KARA E., ER A. G., Demirkan K., ÜNAL S.

FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, vol.26, no.1, pp.50-66, 2021 (ESCI) identifier identifier


Community-acquired pneumonia (CAP) is an important cause of morbidity and mortality in our country and worldwide, and it imposes a serious economic burden on the health system. It is major cause of deaths due to infections in our country. Therefore, initiating CAP treatment with the most appropriate antibiotic as soon as possible is important in decreasing morbidity and mortality. For this purpose, many evidence-based guidelines have been created to assist physicians in the selection of antibiotics and to reduce the differences between clinical practices. Although these guidelines mainly have common content and recommendations, there are some differences according to the health systems of the countries. In addition, the guidelines contain a number of shortcomings and issues not addressed. This review waswritten to compare five CAP guidelines (British Thoracic Society, National Institute for Health and Care Excellence, Euro- pean Society of Clinical Microbiology and Infectious Diseases, Spanish Pneumology and Thoracic Surgery Association, Turkish Thoracic Society), to identify and discuss their differences, and to discuss the issues not considered in the guidelines such as drug interactions, dose adjustment in kidney/liver dysfunction, dose adjustment in obesity, serious/common side effects, and pharmacokinetic-pharmaco- dynamic properties of the drugs.